Spark Therapeutics, Inc.
BiotechSpark Therapeutics, Inc. is a biotechnology company focused on Immunology, Ophthalmology, Dermatology. Key products include Luxturna.
Spark Therapeutics, Inc.'s Key Drugs
Spark Therapeutics, Inc.'s core commercial portfolio centers on Luxturna, spanning Immunology and Ophthalmology — its most strategically important drugs approved in the last 15 years.
Spark Therapeutics, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Spark Therapeutics, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Spark Therapeutics, Inc.'s Therapeutic Areas
Spark Therapeutics, Inc.'s approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Ophthalmology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Spark Therapeutics, Inc.'s Top Competitors
Spark Therapeutics, Inc.'s closest competitors by therapeutic-area and drug-target overlap include BAUSCH, BAUSCH AND LOMB INC, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Spark Therapeutics, Inc. Pipeline Snapshot
Spark Therapeutics, Inc. has 16 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 8 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Luxturna leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/2 completed
- • Speed: 66 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-12-18
- Latest
- 2017-12-18
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges